Gapping down
In reaction to disappointing earnings/guidance: ANAD -24.6%, NDLS -22.3%, ZU -20.1%, TTGT -13%, SKUL -11.8%, TNET -8.5%, TRUP -7.6%, VSI -6.6%, EVOL -6.1%, ENPH -5.8%, OCLR -5.3%, ATRS -4.3%, CERS -3.8%, RUBI -3.6%, CRNT -2.9%, NFX -2.7%, NWPX -2.6%, SM -2.6%, CTLT -2.3%, MIFI -2.1%, CLMT -2.1%, NYMT -2%, SAFT -1.9%, XXIA -1.9%, MYGN -1.6%, SUPN -1.6%, KGC -1.6%, AGU -1.6%, SODA -1.6%, GRPN -1.5%, SAND -1.5%, SCMP -1.4%, DDD -1.2%, WTW -1.1%, CLH -1%, SLRC -0.9%, CLUB -0.9%, AVA -0.9%, MPO -0.9%, PAA -0.8%
M&A news: ALXN -3.7% (acquired GEVA for consideration of $115 in cash and 0.6581 ALXNshares)
Other news: ARDX -26.7% (announces results from its Phase 2a clinical trial evaluating Tenapanor in Chronic Kidney disease patients; trial did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in treated patients ), WLT -17.4% (discussed Going concern issues in 10-Q), ATRS -4.3% ( announces proposed public offering of common stock), ANTM -2.1% (announces a proposed public offering of $900 mln in equity units; units issued at $50/unit will consist of contract to purchase on share of common stock in the future and an interest in subordinated notes ), ACHC -2% (priced 4.5 mln share public offering of common stock at $66.50 per share)
Analyst comments: ENPH -5.8% (downgraded to Underperform from Neutral at BofA/Merrill), WSH -2.2% (downgraded to Sell from Neutral at Goldman), CTB -1.7% (downgraded to Sell from Neutral at Goldman), AMTD -0.9% (downgraded to Neutral from Buy at BofA/Merrill)
In reaction to disappointing earnings/guidance: ANAD -24.6%, NDLS -22.3%, ZU -20.1%, TTGT -13%, SKUL -11.8%, TNET -8.5%, TRUP -7.6%, VSI -6.6%, EVOL -6.1%, ENPH -5.8%, OCLR -5.3%, ATRS -4.3%, CERS -3.8%, RUBI -3.6%, CRNT -2.9%, NFX -2.7%, NWPX -2.6%, SM -2.6%, CTLT -2.3%, MIFI -2.1%, CLMT -2.1%, NYMT -2%, SAFT -1.9%, XXIA -1.9%, MYGN -1.6%, SUPN -1.6%, KGC -1.6%, AGU -1.6%, SODA -1.6%, GRPN -1.5%, SAND -1.5%, SCMP -1.4%, DDD -1.2%, WTW -1.1%, CLH -1%, SLRC -0.9%, CLUB -0.9%, AVA -0.9%, MPO -0.9%, PAA -0.8%
M&A news: ALXN -3.7% (acquired GEVA for consideration of $115 in cash and 0.6581 ALXNshares)
Other news: ARDX -26.7% (announces results from its Phase 2a clinical trial evaluating Tenapanor in Chronic Kidney disease patients; trial did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in treated patients ), WLT -17.4% (discussed Going concern issues in 10-Q), ATRS -4.3% ( announces proposed public offering of common stock), ANTM -2.1% (announces a proposed public offering of $900 mln in equity units; units issued at $50/unit will consist of contract to purchase on share of common stock in the future and an interest in subordinated notes ), ACHC -2% (priced 4.5 mln share public offering of common stock at $66.50 per share)
Analyst comments: ENPH -5.8% (downgraded to Underperform from Neutral at BofA/Merrill), WSH -2.2% (downgraded to Sell from Neutral at Goldman), CTB -1.7% (downgraded to Sell from Neutral at Goldman), AMTD -0.9% (downgraded to Neutral from Buy at BofA/Merrill)